

Nomfundo T. Mahlangeni^a, Roshila Moodley^a, Sreekanth B. Jonnalagadda^{a*}

^aSchool of Chemistry and Physics, University of KwaZulu-Natal, Durban 4000, South Africa.

*Corresponding Author: E-mail: jonnalagaddas@ukzn.ac.za

Abstract

Background: *Cyrtanthus obliquus* is a medicinal plant commonly known by the locals in South Africa as *Umathunga*. It is used in traditional South African medicine for the treatment of scrofula, chronic coughs and headaches and is also used to prepare the popular decoction known as *Imbiza*.

Materials and methods: The secondary metabolites from *C. obliquus* bulbs were extracted using solvent extraction techniques, isolated using column chromatography and identified using spectroscopic techniques. The antioxidant potential of the isolated compounds was determined by the 2,2-diphenyl-1-picrylhydrazyl (DPPH) assay and the ferric reducing antioxidant potential (FRAP) assay.

Results: The extracts yielded four homoisoflavonoids, 5,7-dihydroxy-6-methoxy-3-(4'-methoxybenzyl)chroman-4-one, 5,7-dihydroxy-3-(4'-hydroxybenzyl)chroman-4-one, 5,7-dihydroxy-6-methoxy-3-(4'-methoxybenzylidene)chroman-4-one and 5,7-dihydroxy-3-(4'-hydroxybenzylidene)chroman-4-one. An unusual 3-β-glucopyranosyl-22,27-dihydroxy-lanosta-8-ene was also isolated from the bulbs. The antioxidant studies showed that 3-benzylchromanones have better activity than 3-benzylidenechromanones.

Conclusion: Four homoisoflavonones namely 5,7-dihydroxy-6-methoxy-3-(4'-methoxybenzyl)chroman-4-one; 5,7-dihydroxy-6-methoxy-3-(4'-hydroxybenzyl)chroman-4-one and two 5,7-dihydroxy-6-methoxy-3-(4'-methoxybenzylidene)chroman-4-one; 5,7-dihydroxy-3-(4'-hydroxybenzylidene)chroman-4-one were obtained from *Cyrtanthus obliquus*.

Key words: Amaryllidaceae, homoisoflavonoids, medicinal plant, traditional medicine

Introduction

A large majority of the world's population utilises traditional medicine in one way or another (IARC, 2002). In South Africa, the biodiversity is quite high which lends itself to a large variety of medicinal plants that are sold commercially, both in conventional and informal markets in the country (Chen et al., 2004). Currently, about 80% of South Africans use traditional medicine to meet their primary healthcare needs (Gqaleni et al., 2007; Mbatha et al., 2012). More than 1000 medicinal plants are used for traditional medicine in the province of KwaZulu-Natal, South Africa, alone (Mander, 1998). *Cyrtanthus obliquus* of the plant family Amaryllidaceae, is one of the medicinal plants commonly purchased from the herbalists in South Africa. This evergreen and bulbous plant is known by the locals as *Umathunga*, and is used in African traditional medicine for the treatment of scrofula, chronic coughs and headaches (Du Plessis and Duncan, 1989; Hutchings et al., 1996; Watt et al., 1962). In South Africa, this plant is also used to prepare the popular decoction known as *Imbiza* (Ndhlala et al., 2009).

Other *Cyrtanthus* species have been used by Black South African women to treat pregnancy-related ailments and by traditional healers to treat patients suffering from cystitis, age-related dementia and leprosy (Herrera et al., 2001; Nair et al., 2011; Veale et al., 1992). Thus far, research has been conducted on the alkaloidal content of *C. obliquus* bulbs only (Brine et al., 2002). Previously, we reported on the antibacterial properties of the fruits and leaves of *Carissa macrocarpa* and the antioxidant activity of the fruits and bark of *Harpephyllum caffrum*, two South African medicinal plant species (Moodley et al., 2011; Moodley et al., 2014). In current study, a phytochemical investigation on the bulbs of the South African medicinal plant, *C. obliquus* was conducted using spectroscopic techniques to determine the other classes of compounds present in the plant. Additionally, the antioxidant activity of the isolated compounds was also evaluated.

Materials and Methods

General experimental procedure

Melting points were recorded on an Ernst Leitz Wetzler micro-hot stage melting point apparatus. Specific rotations were measured at room temperature in methanol (MeOH) on a PerkinElmerTM, Model 341 Polarimeter with a 10 cm flow tube. Infrared (IR) spectra were recorded on a Perkin Elmer Spectrum 100 FT-IR spectrometer with Universal ATR sampling accessory. Ultraviolet (UV) spectra were obtained on a UV-Vis-NIR Shimadzu UV-3600 Spectrophotometer in MeOH. All 1-D and 2-D NMR spectra were recorded in deuterated chloroform or deuterated MeOH at room temperature on a Bruker Avance^{III} 400 MHz NMR spectrometer. Liquid-chromatography-mass spectroscopy (LC-MS) was done on an Agilent LC/MSD Trap 1100 Series. High resolution-mass spectroscopy (HR-MS) was done on a Bruker Micro TOF-QII instrument. The UV Spectrophotometer Biochrom Libra S11 was used for antioxidant assays. Merck silica gel 60 (0.040-0.063 mm) was used for column chromatography and Merck silica gel 60, F254 aluminium sheets were utilized for thin layer chromatography (TLC). TLC plates were monitored by analysis under UV (254 nm and 366 nm) and visualized using anisaldehyde spray reagent (97: 2: 1(v/v) MeOH: conc. H₂SO₄: anisaldehyde).

Plant material

Fresh bulbs from *C. obliquus* were purchased at the Berea market in Durban and identified by a curator from the School of Biological and Conservation Sciences, UKZN, Westville and a voucher specimen (Mahlangeni, N1) was deposited in the ward herbarium at UKZN.

Extraction and isolation

The plant material (2.04 kg) was cut into small pieces, air-dried overnight and then sequentially extracted with hexane, dichloromethane (DCM) and MeOH by continuous shaking on an orbital shaker for 48 h. The crude extracts were evaporated under reduced pressure then subjected to column chromatography and monitored by TLC. Hexane and DCM extracts were combined due to similar TLC profiles. Combined extracts were then separated with a hexane: ethyl acetate (EtOAc) step gradient system starting from 100% hexane to 90% EtOAc. Fractions with similar TLC profiles were combined and concentrated using the rotary evaporator. Compound **1** (71.5 mg) and compound **2** (45.7 mg) was obtained after separation with a hexane: EtOAc (80: 20, v/v) solvent system.

The crude MeOH extract was further fractionated in triplicate with 500 mL DCM then with 500 mL EtOAc for 48 h each. The resulting DCM and EtOAc fractions were concentrated then loaded into separate columns. The column containing the DCM fraction (9.48 g) was separated with a hexane: EtOAc step gradient starting from 100% hexane to 100% EtOAc. Compound **3** (3.9 mg) was obtained from a hexane: EtOAc (80: 20, v/v) solvent system. The EtOAc fraction (3.40 g) was separated by increasing the polarity of DCM with MeOH, starting with 100% DCM until a DCM: MeOH (70: 30, v/v) solvent system was reached. Compound **5** (3.1 mg) was obtained as a white solid from a DCM: MeOH (80: 20, v/v) solvent system. Fractions 51-64 from this extract were combined and further purified using DCM: MeOH (98: 2, v/v) to yield compound **4** (4.3 mg).

Spectral data

5,7-dihydroxy-6-methoxy-3-(4'-methoxybenzyl)chroman-4-one (**1**) (71.5 mg): Yellow crystals; m.p. 90-92 °C; $[\alpha]^{20}_D$: -0.11° (c 0.10, MeOH); IR ν_{\max} cm^{-1} : 3391, 2932, 1638, 1602, 1461, 1018; UV (MeOH) λ_{\max} nm (log ϵ): 216 (4.20), 292 (3.84), 347 (3.44); $^1\text{H-NMR}$ (CDCl_3 , 400MHz) spectral data, see Table 1; $^{13}\text{C-NMR}$ (CDCl_3 , 400MHz) spectral data, see Table 2; LC-MS (negative mode): m/z 329.0 $[\text{M-H}_2\text{O}]^-$; HREIMS: m/z 330.1286 $[\text{M-H}_2\text{O}]^-$, (Calc. for $\text{C}_{18}\text{H}_{18}\text{O}_6$).

5,7-dihydroxy-6-methoxy-3-(4'-methoxybenzylidene)chroman-4-one (**2**) (45.7 mg): Orange crystals; m.p. 130-133 °C; $[\alpha]^{20}_D$: +0.01° (c 0.10, MeOH); IR ν_{\max} cm^{-1} : 3360, 293, 1636, 1600, 1513, 1460, 1019; UV (MeOH) λ_{\max} nm (log ϵ): 215 (4.15), 360 (3.30); $^1\text{H-NMR}$ (CDCl_3 , 400MHz) spectral data, see Table 1; $^{13}\text{C-NMR}$ (CDCl_3 , 400MHz) spectral data, see Table 2; LC-MS (negative mode): m/z : 329.0 $[\text{M-OH}]^-$; HREIMS: m/z 328.1051 $[\text{M-H}_2\text{O}]^-$ (Calc. for $\text{C}_{18}\text{H}_{16}\text{O}_6$).

5,7-dihydroxy-6-methoxy-3-(4'-hydroxybenzyl)chroman-4-one (**3**): Pale yellow needles (3.9 mg); m.p. 194-196 °C; $[\alpha]^{20}_D$: 0° (c 0.10, MeOH); IR ν_{\max} cm^{-1} : 3288, 2945, 2831, 1693, 1586, 1450, 1019; UV (MeOH) λ_{\max} nm (log ϵ): 216 (4.13), 362 (3.47); $^1\text{H-NMR}$ (CDCl_3 , 400MHz) spectral data, see Table 1; $^{13}\text{C-NMR}$ (CDCl_3 , 400MHz) spectral data, see Table 2; LC-MS (negative mode): m/z : 282.9 $[\text{M-H}_2\text{O-CH}_2\text{OH}]^-$; HREIMS: m/z 315.0961 $[\text{M-H}_2\text{O}]^-$ (Calc. for $\text{C}_{17}\text{H}_{15}\text{O}_6$).

5,7-dihydroxy-3-(4'-hydroxybenzylidene)chroman-4-one (**4**): Yellow crystals (4.3 mg); m.p. 205-207 °C; $[\alpha]^{20}_D$: +0.01° (c 0.10, MeOH); IR ν_{\max} cm^{-1} : 3211, 2942, 2831, 1673, 1587, 1450, 1022; UV (MeOH) λ_{\max} nm (log ϵ): 213 (4.09), 292 (2.88), 362 (3.20); $^1\text{H-NMR}$ (MeOD, 400MHz) spectral data, see Table 1; $^{13}\text{C-NMR}$ (MeOD, 400MHz) spectral data, see Table 2; LC-MS (negative mode): m/z 282.9 $[\text{M-H}_2\text{O}]^-$; HR-MS: m/z 284.0830 $[\text{M-H}_2\text{O}]^-$ (Calc. for $\text{C}_{16}\text{H}_{12}\text{O}_5$).

3- β -glucopyranosyl-22,27-dihydroxy-lanosta-8-ene (**5**): White solid (3.1 mg); m.p. 245-248 °C; $[\alpha]^{20}_D$: +0.02° (c 0.10, MeOH); IR ν_{\max} : 3325, 2943, 2832, 1658, 1449, 1410, 1108, 1019; UV (MeOH) λ_{\max} nm (log ϵ): 213 (4.36), 262 (2.73); $^1\text{H-NMR}$ (400MHz, MeOD): δ 0.69 (3H, s, H-18), 0.92 (3H, s, H-35), 0.98 (2H, d, J = 10.17Hz, H-6), 0.98 (6H, s, H-31/32), 0.99 (3H, s, H-19), 1.18 (2H, d, J = 5.24 Hz, H-5/26), 1.21 (9H, s, H-28/29/33), 1.30 (8H, d, J = 14.49 Hz, H-1/2/15/16), 1.37 (4H, s, H-20/30), 1.46 (2H, d, J = 4.56 Hz, H-23), 1.57 (1H, d, J = 9.21 Hz, H-17), 1.90 (3H, s, H-21), 1.97 (6H, d, J = 5.52 Hz, H-7/12/25), 2.04 (2H, s, H-24), 2.06 (2H, s, H-11), 3.16 (1H, d, J = 4.72 Hz, H-2'), 3.18 (1H, d, J = 4.68 Hz, H-3'), 3.28 (1H, d, J = 4.68 Hz, H-4'), 3.29 (1H, d, J = 4.68 Hz, H-5'), 3.35 (1H, s, H-3), 3.37 (1H, d, $J_{3,4\alpha}$ = 11.25 Hz, H-34), 3.41 (1H, d, $J_{3,4\beta}$ = 11.25 Hz, H-34), 3.69 (1H, dd, $J_{6\alpha}$ = 11.97, 5.72 Hz, H-6'), 3.88 (1H, dd, $J_{6\beta}$ = 11.89, 2.12 Hz, H-6'), 4.23 (1H, d, J = 7.84 Hz, H-11), 4.91 (1H, s, H-22); $^{13}\text{C-NMR}$ (400MHz, MeOD): δ 135.3 (C-9), 135.2 (C-8), 100.1 (C-1'), 80.7 (C-3), 77.8 (C-5'), 77.7 (C-27/3'), 74.7 (C-2'), 72.2 (C-22), 71.3 (C-4'), 64.7 (C-34), 62.3 (C-6'), 52.1 (C-5/26), 51.9 (C-17), 50.6 (C-14), 45.2 (C-13), 43.1 (C-4), 42.5 (C-23), 37.5 (C-10), 34.4 (C-20/30), 31.8 (C-1/16), 31.4 (C-2/15), 29.0 (C-24), 27.4 (C-7/12/25), 24.1 (C-35), 22.6 (C-28/29/33), 21.6 (C-11), 19.7 (C-19), 19.6 (C-31/32), 19.2 (C-6), 15.8 (C-18), 13.7 (C-21); LC-MS (negative mode): m/z : 649.5 $[\text{M-C}_3\text{H}_7\text{O}]^-$.

Antioxidant activity

Determination of DPPH free radical scavenging capacity

The DPPH free radical scavenging activity was determined according to the method described by Murthy et al. (2012) with some modifications. A volume of 150 μL of methanolic solution of the compound at varying concentrations (10-1000 $\mu\text{g mL}^{-1}$) was mixed with 2850 μL of the methanolic solution of DPPH (0.1 mM). An equal amount of MeOH and DPPH without sample served as a control. After 30 min of reaction at room temperature in the dark, the absorbance was measured at 517 nm against MeOH as a blank using a UV spectrophotometer. Ascorbic acid was used as a positive control. All procedures were performed in triplicate. The percentage free radical scavenging activity was calculated according to the following equation:

$$\% \text{ Inhibition} = \left(\frac{Ac - As}{Ac} \right) \times 100$$

Where Ac = Absorbance of control and As = Absorbance of sample

The concentration providing 50% maximal inhibition (IC_{50}) was obtained by plotting a dose-response curve.

Determination of the reducing potential by the FRAP assay

The ferric reducing antioxidant potential (FRAP) assay was determined according to the method by Murthy et al. (2012) with some

<http://dx.doi.org/10.4314/ajtcam.v12i5.5>

modifications. A 2.5 mL volume of different concentrations of the compounds (10-500 $\mu\text{g mL}^{-1}$) was mixed with 2.5 mL phosphate buffer solution (0.2 M, pH = 6.6) and 2.5 mL of 1% potassium ferricyanide [$\text{K}_3\text{Fe}(\text{CN})_6$] in test tubes. The mixture was placed in a water bath at 50 °C for 20 min. A volume of 2.5 mL of 10% trichloroacetic acid (TCA) was added to the mixture and mixed thoroughly. A volume of 2.5 mL of this mixture was then mixed with 2.5 mL of distilled water and 0.5 mL of FeCl_3 solution (0.1%) and allowed to stand for 10 min. The absorbance of the mixture was measured at 700 nm using a UV-VIS spectrophotometer. Ascorbic acid was used as a positive control. All procedures were performed in triplicate.

Results and Discussion

The $^1\text{H-NMR}$ spectrum of compound **1** showed resonances in the aromatic region at δ_{H} 6.84 (H-3'/5', d, $J = 8.52$ Hz) and δ_{H} 7.11 (H-2'/6', d, $J = 8.52$ Hz), each integrating to two protons. This was also observed for compound **2** at δ_{H} 6.87 (H-3'/5', d, $J = 9.70$ Hz) and δ_{H} 7.80 (H-2'/6', d, $J = 8.80$ Hz); compound **3** at δ_{H} 6.78 (H-3'/5', d, $J = 8.40$ Hz) and δ_{H} 7.08 (H-2'/6', d, $J = 8.40$ Hz) and compound **4** at δ_{H} 6.88 (H-3'/5', d, $J = 8.60$ Hz) and δ_{H} 7.26 (H-2'/6', d, $J = 8.60$ Hz) also integrating to two protons. This suggested the presence of a mono-substituted aromatic ring for each compound (Fig. 1).

Table 1: $^1\text{H-NMR}$ data (compound **1**, **2**, **3** in CDCl_3 ; and **4** in MeOD) (400 MHz; δ_{H} : ppm; J (Hz))

Position	1	2	3	4
1'	-	-	-	-
2', 6'	7.11, d (8.52)	7.80, d (8.80)	7.08, d (8.40)	7.26, d (8.60)
3', 5'	6.84, d (8.52)	6.87, d (9.70)	6.78, d (8.40)	6.88, d (8.60)
4'	-	-	-	-
3	2.83, m	-	2.80, m	-
2	4.17 Ha, dd (7.10, 11.39); 4.33 Hb, dd (4.10, 11.39)	4.96, d (1.04)	4.18 Ha, dd (7.16, 11.41); 4.35 Hb, dd (4.20, 11.37)	5.32, d (1.72)
9	2.69 Ha, dd (10.39, 13.85); 3.15 Hb, dd (4.32, 13.85)	6.88, s	2.69 Ha, dd (10.38, 13.85); 3.17 Hb, dd (4.34, 13.83)	7.74, s
4	-	-	-	-
4a	-	-	-	-
8a	-	-	-	-
8	6.10, s	6.12, s	6.10, s	5.91, d (2.20)
7	-	-	-	-
6	-	-	-	5.84, d (1.76)
5	-	-	-	-
4-OCH ₃	3.77, s	3.82, s	-	-
6-OCH ₃	3.81, s	3.85, s	3.83, s	-

Similarities with resonances between compounds **1** and **3** were observed at H-3, H-2 and H-9. The $^{13}\text{C-NMR}$ and DEPT spectra showed methylene

resonances at C-9 and C-2, as expected, with the resonance at C-2 shifting more downfield due to the attachment of the oxygen (Table 2). The COSY and NOESY data confirmed the coupling of protons at H-3 and H-9 as well as H-2.

The $^1\text{H-NMR}$ and $^{13}\text{C-NMR}$ spectral data were in good agreement with reported homoisoflavanones 5,7-dihydroxy-6-methoxy-3-(4-methoxybenzyl)chroman-4-one (**1**) and 5,7-dihydroxy-6-methoxy-3-(4-hydroxybenzyl)chroman-4-one (**3**) (Adinolfi et al., 1985; Adinolfi et al., 1987) isolated for the first time from *C. obliquus*. Both compounds were unstable with compound **1** losing H_2O (m/z 330.1286) and compound **3** losing a proton (m/z 315.0961).

The $^{13}\text{C-NMR}$ spectrum for compound **2** showed strong resonances at δ_{C} 113.46 and δ_{C} 132.91 which, in the HSQC experiment, correlated to the protons at δ_{H} 6.87 (H-3'/5') and δ_{H} 7.80 (H-2'/6'), respectively. The methoxy group singlet resonating at δ_{H} 3.82 was attributed to C-4' in the B ring. The $^1\text{H-NMR}$ spectrum showed resonances at δ_{H} 6.88 (s, H-9) and δ_{H} 4.96 (d, H-2, $J = 1.04$ Hz) which integrated to two protons. The singlet at δ_{H} 6.88 (H-9) correlated to the carbon resonance at δ_{C} 141.09 (C-9) in the HSQC experiment and it correlated to the carbon resonance at δ_{C} 125.08 (C-3) in the HMBC experiment. The upfield shift of the carbonyl resonance at δ_{C} 187.02 (C-4) compared to compound **1** confirmed the 3, 9 moiety to be unsaturated. The data obtained for compound **2** compared well with literature values therefore it was identified as 5,7-dihydroxy-6-methoxy-3-(4-

<http://dx.doi.org/10.4314/ajtcam.v12i5.5>

methoxybenzylidene)chroman-4-one (Adinolfi et al., 1989) which has been isolated for the first time in *C. obliquus*. The compound was seen to be unstable with a molecular ion peak at m/z 328.1051 due to loss of a H_2O molecule.

Table 2: ^{13}C -NMR data (compound 1, 2, 3 in $CDCl_3$ and 4 in MeOD) (400 MHz; δ : ppm)

Position	1	2	3	4
1'	129.47	126.39	129.67	126.05
2', 6'	129.87	132.91	130.17	132.67
3', 5'	113.97	113.46	115.48	115.88
4'	158.22	161.05	154.35	159.77
3	46.50	125.08	46.65	127.44
2	69.12	75.50	69.31	67.68
9	31.81	141.09	31.81	137.15
4	197.38	187.02	197.60	185.53
4a	102.19	104.52	102.31	102.58
8a	153.01	152.88	152.88	165.40
8	95.86	96.17	95.77	96.39
7	157.84	157.37	157.61	167.43
6	127.22	127.22	127.15	95.02 (CH)
5	159.96	161.05	160.13	163.04
4'-OCH ₃	55.71	55.43	-	-
6'-OCH ₃	61.36	61.78	61.39	-

Table 3: IC₅₀ values of compounds 1, 2, 3 and 4 on the DPPH free radical.

Compound	IC ₅₀ Value ($\mu\text{g/mL}$) ^a
1	371.54
2	ns ^b
3	288.40
4	ns ^b
Ascorbic acid	27.54

^a n=3 ^b ns: not significant




Figure 1: Chemical structures of compounds 1-4

The $^1\text{H-NMR}$ and $^{13}\text{C-NMR}$ spectra of compound **4** showed slight differences to that of compound **2**, in that there were no methoxy resonances. The $^1\text{H-NMR}$ spectrum showed a resonance at δ_{H} 5.84 (H-6, $J = 1.76$ Hz) that showed weak meta-coupling to the resonance at δ_{H} 5.91 (H-8, $J = 2.20$ Hz) in the COSY spectrum. The proton at C-6 in compound **4** replaced the methoxy group at C-6 in compound **2**. The methoxy group at C-4' in compound **2** was replaced by a hydroxy group at C-4' in compound **4** which was attached to the quaternary carbon resonance at δ_{C} 159.77 as confirmed by HMBC correlations. The data obtained for compound **4** compared well with literature values therefore it was identified as 5,7-dihydroxy-3-(4'-hydroxybenzylidene)chroman-4-one (Adinolfi et al., 1989) isolated for the first time in *C. obliquus*. The compound was seen to be unstable with a molecular ion peak at m/z 284.0830 due to loss of H_2O plus an extra proton.

The $^1\text{H-NMR}$ spectrum for compound **5** (Fig. 2) showed resonances at δ_{H} 0.69 (H-18), δ_{H} 0.92 (H-35), δ_{H} 0.98 (H-31/32), δ_{H} 0.99 (H-19), δ_{H} 1.21 (H-28/29/33) and δ_{H} 1.91 (H-21) which were all singlets. The protons resonating at δ_{H} 0.69, δ_{H} 0.92, δ_{H} 1.21 and δ_{H} 0.99 were seen to be attached to unsaturated carbons. The resonances at δ_{H} 0.98 (H-31/32) and δ_{H} 1.21 (H-28/29/33) integrated to six and nine protons, respectively therefore two carbons were resonating at δ_{C} 19.56 (C-31/32) and three were resonating at δ_{C} 22.60 (C-28/29/33). The HMBC spectrum showed that the proton resonance at δ_{H} 0.69 (H-18) correlated to the carbon resonances at δ_{C} 31.41 (C-2/15), δ_{C} 31.77 (C-1/16), δ_{C} 45.21 (C-13), δ_{C} 50.59 (C-14) and δ_{C} 51.88 (C-17), therefore it was positioned at C-18. The heavily substituted 2-methylheptane side chain was found to be hydroxylated at C-22 and C-27, which led to the shift in the resonance peaks at δ_{C} 42.50 (C-23) and δ_{C} 52.14 (C-26). The resonances at δ_{C} 135.21 (C-8) and δ_{C} 135.31 (C-9) confirmed a lanosterol skeleton with a substituted methylheptane side chain.

The $^1\text{H-NMR}$ spectrum showed resonances at δ_{H} 3.16 (H-2'), δ_{H} 3.18 (H-3'), δ_{H} 3.28 (H-4'), δ_{H} 3.29 (H-5'), δ_{H} 3.69 (H-6' α), δ_{H} 3.88 (H-6' β) and δ_{H} 4.23 (H-1'). The HSQC spectrum showed that δ_{H} 3.69 (1H α , dd, $J = 5.72, 11.97$ Hz) and δ_{H} 3.88 (1H β , dd, $J = 2.12, 11.89$ Hz) were attached to the same carbon at δ_{C} 62.32 (C-6'). The HSQC spectrum showed that the proton resonances at δ_{H} 3.16, δ_{H} 3.29 and δ_{H} 4.23 correlated to carbon resonances at δ_{C} 74.69 (C-2'), δ_{C} 77.82 (C-5') and δ_{C} 100.07 (C-1'), respectively.

The COSY experiment showed the coupling of protons at δ_{H} 3.16 (H-2') with δ_{H} 4.23 (H-1') and protons at δ_{H} 3.88 (H β -6') with δ_{H} 3.69 (H α -6'). This led to the assumption of the presence of a glycosidic linkage at the C-3 position. There was weak coupling of the protons on the glucoside as seen from the weak HMBC correlations further up-field, therefore correlations were minimal. The structural deduction of the entire molecule was found from the different experiments performed. The data for compound **5** was compared to NMR data for β -sitosterol glycoside (Akhtar et al., 2010) and many similarities especially at the glycosidic linkage were found. The melting point of the compound was 245-248 °C which was close to that of β -sitosterol glycoside (252-253°C) (Akhtar et al., 2010). This confirms the proposed structure of compound **5** which has molecular formula $\text{C}_{41}\text{H}_{72}\text{O}_9$ with a molecular mass of 708.5 g mol $^{-1}$. Compound **5** was therefore identified as 3- β -glucopyranosyl-22,27-dihydroxy-lanosta-8-ene, isolated for the first time in *C. obliquus*.




Figure 2: Chemical structure of compound **5**




Figure 3: Comparison of the ferric reducing/ antioxidant power of compounds 1-4

Compounds 2 and 4 were observed to be inactive when tested for antioxidant activity by the DPPH free radical scavenging assay (Table 3). The IC₅₀ value of the 3-benzylidenechromanones was found to exceed the concentration range; this was also evident in previous studies (Nakamura et al., 2003; Mohamad et al., 2004). However, compounds 1 and 3 were observed to show significant activity compared to the 3-benzylidenechromanones though lower than ascorbic acid (Table 3). Both compounds possess the C₃-C₉ saturated moiety where the hydrogen may be easily donated to the DPPH radical to form DPPH-H.

The FRAP assay measures the Fe³⁺ to Fe²⁺ reduction in the presence of an antioxidant (Gupta et al., 2009). High absorbance of the reaction mixture is related to greater reducing power which indicates strong antioxidant activity. A similar trend was also exhibited by the FRAP assay where the activities of compounds were in decreasing order of Compound 1 > 3 > 2 > 4 (Fig. 3 and 4).

Conclusion

Four homoisoflavanones namely 5,7-dihydroxy-6-methoxy-3-(4'-methoxybenzyl)chroman-4-one; 5,7-dihydroxy-6-methoxy-3-(4'-hydroxybenzyl)chroman-4-one and two 5,7-dihydroxy-6-methoxy-3-(4'-methoxybenzylidene)chroman-4-one; 5,7-dihydroxy-3-(4'-hydroxybenzylidene)-chroman-4-one were obtained from *Cyrtanthus obliquus*. An unusual 3-β-glucopyranosyl-22,27-dihydroxy-lanosta-8-ene was also isolated from the bulbs. Thus, this study shows that the plant is not only rich in alkaloids, but also flavonoids, particularly homoisoflavanones. The antioxidant potential of the homoisoflavanones indicate that 3-benzylchromanones have better antioxidant activity than 3-benzylidenechromanones.




Figure 4: Ferric reducing/antioxidant power of compounds 1-4 and ascorbic acid standard, as measured by the FRAP assay

Acknowledgements

The authors would like to thank Dorothy Okoth and Joyce Kiplimo for assistance, UKZN for the research facilities and NRF for financial support.

References

1. Adinolfi, M., Barone, G., Belardini, M., Lanzetta, R., Laonigro C., Mangoni, L. and Parrilli, M. (1985). Three 3-benzyl-4-chromanones from *Muscari comosum*, *Phytochem.*, 24: 624 – 626.
2. Adinolfi, M., Barone, G., Belardini, M., Lanzetta, R., Laonigro, C. and Parrilli, M. (1987). Ten homoisoflavanones from two *Muscari* species, *Phytochem.*, 26: 285 – 290.
3. Adinolfi, M., Aquila, T., Barone, G., Belardini, M., Lanzetta, R. and Parrilli, M. (1989). Homoisoflavanones from *Bellevia romana*, *Phytochem.*, 28: 3244 – 3246.
4. Akhtar, P., Ali, M., Sharma, M. P., Farooqi, H. and Khan H. N. (2010). Phytochemical investigation of fruits of *Corylus colurna* Linn. *J. Phytol.*, 2: 89 – 100.
5. Brine, N. D., Campbell, W. E., Bastida, J., Herrera, M. R., Viladomat, F., Codina, C. and Smith, P. J. (2002). A dinitrogenous alkaloid from *Cyrtanthus obliquus*. *Phytochem.*, 61: 443 – 447.
6. Chen, M. A., Vaneek, J. and Carr, M. (2004). Mainstreaming informal employment and gender in poverty reduction. Commonwealth Secretariat: London, United Kingdom. www.idrc.ac/pub@idrc.ca.
7. Du Plessis, N. and Duncan, G. (1989). Bulbous plants of Southern Africa. Tafelberg Publishers Ltd: Cape Town, South Africa.
8. Gqaleni, N., Moodley, I., Kruger, H., Ntuli, A. and McLeod, H. (2007). Traditional and complementary medicine. In South African Health Review, Harrison, S., Bhana, R., Ntuli, A. (Eds.). Health Systems Trust: Durban, South Africa. pp. 175 – 185.
9. Gupta, R., Sharma, M., Lakshmay, R., Prabhakaran, D. and Reddy, K. S. (2009). Improved method of total antioxidant assay. *Indian J. Biochem. Biophys.*, 46: 126 – 129.
10. Herrera, M. R., Machocho, A. K., Nair, J. J., Campbell, W. E., Brun, R., Viladomat, F., Codina, C. and Bastida, J. (2001). Alkaloids from *Cyrtanthus elatus*. *Fitoterapia*. 72: 444 – 448.
11. Hutchings, A., Scott, A. H., Lewis, G., Cunningham, A. B. (1996). Zulu medicinal plants: an inventory. University of Natal Press: Pietermaritzburg, South Africa.
12. International Agency for Research on Cancer. (2002). IARC monographs on the evaluation of carcinogenic risks of humans. Some traditional herbal medicines, some mycotoxins, naphthalene and styrene. IARC Press: France. pp. 43 – 68.
13. Mander, M. (1998). Marketing of indigenous plants in South Africa. A case study in KwaZulu-Natal. F.A.O. of the U.N: Rome, Italy.
14. Mbatha, N., Street, R. A., Ngcobo, M. and Gqaleni, N. (2012). Sick certificates issued by South African traditional health practitioners. Current legislations, challenges and the way forward. *S. Afr. Med. J.*, 102: 129 – 131.
15. Mohamad, H., Abas, F., Permana, D., Lajis, N. H., Ali, A. M., Sukari, M. A., Hin, T. Y. Y., Kikuzaki, H. and Nakatani, N. (2004). DPPH free radical scavenger components from the fruits of *Alpinia rafflesiana* Wall. ex. Bak. (Zingiberaceae). *Z. Naturforsch.*, 59c: 811 – 815.
16. Moodley, R., Chenia, H., Koorbanally, N. and Jonnalagadda, S. B. (2011). Antibacterial and anti-adhesion activity of the pentacyclic triterpenoids isolated from the leaves and edible fruits of *Carissa macrocarpa*. *J. Med. Plant Res.*, 5: 4851 – 4858. .
17. Moodley, R., Koorbanally, N., Islam, S. M. and Jonnalagadda, S. B. (2014). Structure and antioxidant activity of phenolic compounds isolated from the edible fruits and stem bark of *Harpephyllum caffrum*. *J. Environ. Sc. Heal. B*, 49: 938 – 944.
18. Murthy, P. S., Manjunatha, M. R., Sulochannama, G. and Naidu, M. M. (2012). Extraction, characterisation and bioactivity of coffee anthocyanins. *Eur. J. Bio. Sci.*, 4: 13 – 19.
19. Nair, J. J., Aremu, A. O. and van Staden, J. (2011). Isolation of nacriprimine from *Cyrtanthus conocratus* (Amaryllidaceae) on evaluation of its acetylcholinesterase inhibitory activity. *J. Ethnopharmacol.*, 137: 1102 – 1106.
20. Nakamura, Y., Watanabe, S., Miyake, N., Kohno, H. and Osawa, T. (2003). Dihydrochalcones: evaluation as novel radical scavenging antioxidants. *J. Agric. Food Chem.*, 51: 3309 – 3312.
21. Ndhhlala, N., Stafford, G. I., Finnie, J. F. and van Staden, J. (2009). *In vitro* pharmacological effects of manufactured herbal concoctions used in KwaZulu-Natal, South Africa. *J. Ethnopharmacol.*, 122: 117 – 122.
22. Veale, D. J. H., Furman, K. I., Oliver, D. W. (1992). South African traditional medicines used during pregnancy and childbirth. *J. Ethnopharmacol.*, 36: 185 – 191.
23. Watt, J. M., Breyer-Brandwijk, M. G. (1962). The medicinal and poisonous plants of Southern and Eastern Africa. E. and S. Livingston Ltd: London.